Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Parkinson Disease 4, Autosomal Dominant Lewy Body 9Stomach Neoplasms 3Uterine Cervical Neoplasms 2Urothelial Cancer 2Urinary Bladder Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Carcinoma 2Various Advanced Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Small Cell Lung Carcinoma 1Ototoxicity 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Liver Neoplasms 1Hepatoblastoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

zolbetuximab 2Oxaliplatin 2Afatinib 2trastuzumab deruxtecan 1tepotinib 1repotrectinib 1pralsetinib 1brigatinib 1Standard of Care 1Pemetrexed 1Leucovorin 1Fluorouracil 1Crizotinib 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Adenocarcinoma × Cisplatin × Clear all
NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Boehringer Ingelheim

Phase 3 Completed
345 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡